Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
Deborah DeEugenio(Thomas Jefferson University), Arnold J. Greenspon(Thomas Jefferson University Hospital), Nicholas Ruggiero(Thomas Jefferson University), Matthew DeCaro(Thomas Jefferson University Hospital), Jocelyn Andrel(Thomas Jefferson University), Grace M. Lee, Louis Kolman(Jefferson College), P. V. Duong(Temple University), Shalabh Singhal(Integrated BioTherapeutics (United States)), Linh Lam(Temple University), Christopher McGowan(University of North Carolina at Chapel Hill), Mark DeCaro(Thomas Jefferson University Hospital), Inna Chervoneva(Thomas Jefferson University)
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
April 26, 2007
Cited by 93
Related Papers
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
|MMWR Morbidity and Mortality Weekly Report|2021|216
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212